US FDA clears Lupin's Goa plant, paves way for new product approvals

Goa plant has an annual capacity of 6 billion units of tablets, capsules or oral suspension drugs. It accounts for 18-20% of firm's US revenue

The US Food and Drug Administration (FDA) has cleared Lupin’s Goa plant paving the way for new product approvals.

The Goa plant has an annual capacity for producing 6 billion units of tablets, capsules or oral suspension drugs. It accounts for 18-20 per cent of the drug maker’s US revenue.

On Wednesday, Lupin announced that the US FDA has issued an establishment inspection report with a voluntary action-indicated status for the Goa plant. The plant was served a warning letter in 2017. It had received seven observations from the US regulator after its inspection in September. The company’s stock gained